Table 1 Effectiveness of 3 doses of rotavirus vaccine in preventing hospital admission for AGE among children aged 6–59 months, stratified by age group and genotypes

From: Impact of the indigenous rotavirus vaccine Rotavac in the Universal Immunization Program in India during 2016–2020

 

Rotavirus-positive cases

Rotavirus-negative controls

Unadjusted vaccine effectiveness (95% CI)

aVEa (95% CI)

Children aged 6–59 months

N = 1,790

N = 5,437

–

–

0 dose (reference)

216 (12%)

365 (7%)

Reference

Reference

3 doses

1,574 (88%)

5,072 (93%)

48% (38% to 57%)

54% (45% to 62%)

Stratified by age group

Children aged 6–11 months

N = 887

N = 2697

–

–

0 dose (reference)

119 (13%)

184 (7%)

Reference

Reference

3 doses

768 (87%)

2,513 (93%)

53% (40% to 63%)

59% (47% to 68%)

Children aged 12–17 months

N = 601

N = 1,542

–

–

0 dose (reference)

54 (9%)

75 (5%)

Reference

Reference

3 doses

547 (91%)

1,467 (95%)

49% (26% to 64%)

54% (33% to 68%)

Children aged 18–23 months

N = 199

N = 675

–

–

0 dose (reference)

28 (14%)

60 (9%)

Reference

Reference

3 doses

171 (86%)

615 (91%)

41% (4% to 64%)

48% (15% to 69%)

Children aged 12–23 months

N = 800

N = 2,217

–

–

0 dose (reference)

82 (10%)

135 (6%)

Reference

Reference

3 doses

718 (90%)

2,082 (94%)

44% (25% to 58%)

51% (35% to 64%)

Children aged 6–23 months

N = 1,687

N = 4,914

–

–

0 dose (reference)

201 (12%)

319 (7%)

Reference

Reference

3 doses

1,486 (88%)

4,595 (93%)

49% (39% to 58%)

55% (45% to 63%)

Children aged 24 months and above

N = 103

N = 523

–

–

0 dose (reference)

15 (15%)

46 (9%)

Reference

Reference

3 doses

88 (85%)

477 (91%)

44% (−5% to 70%)

48% (1% to 73%)

Stratified by commonly circulating genotypes (6–23 months)

G3P[8]

N = 849

N = 4,914

–

–

0 dose (reference)

89 (10%)

319 (7%)

Reference

Reference

3 doses

760 (90%)

4,595 (93%)

41% (25% to 54%)

51% (36% to 62%)

G1P[8]

N = 194

N = 4,914

–

–

0 dose (reference)

47 (24%)

319 (7%)

Reference

Reference

3 doses

147 (76%)

4,595 (93%)

79% (70% to 85%)

81% (73% to 87%)

G2P[4]

N = 162

N = 4,914

–

–

0 dose (reference)

13 (8%)

319 (7%)

Reference

Reference

3 doses

149 (92%)

4,595 (93%)

21% (−41% to 56%)

32% (−23% to 62%)

G1P[6]

N = 59

N = 4,914

–

–

0 dose (reference)

8 (14%)

319 (7%)

Reference

Reference

3 doses

51 (86%)

4,595 (93%)

56% (6% to 80%)

64% (21% to 83%)

G9P[4]

N = 52

N = 4,914

–

–

0 dose (reference)

7 (13%)

319 (7%)

Reference

Reference

3 doses

46 (87%)

4,595 (93%)

55% (−1% to 80%)

59% (7% to 82%)

  1. Vaccine effectiveness of rotavirus vaccination among age-eligible children who received all 3 doses of the vaccine (N = 6,646) against nonvaccinated group (N = 581). The children not included in the table are those who received partial vaccination (N = 1,145). A child was considered vaccinated if the rotavirus vaccine was administered ≥14 days of hospital admission. The models that included the child’s age at the time of hospital admission, month of admission to the hospital, maternal level of education and asset score changed the adjusted odds ratio (OR) by >5% and were therefore included in the final models. A stratification of aVE by severity of AGE and dose of the vaccine is provided in Extended Data Table 5.
  2. aAn unconditional logistic regression was used to calculate the aVE measure.
Back to article page